Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-16T17:43:32.544Z Has data issue: false hasContentIssue false

Evidence-based pharmacotherapy for obsessive–compulsive disorder

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

The development of effective pharmacotherapy has revolutionised the treatment of obsessive–compulsive disorder (OCD), and has generated an explosion of interest in this previously poorly understood area of psychiatry. Once considered a rare, refractory form of learnt behaviour, we now recognise OCD to be a common, treatable illness, with a distinctive pathophysiology and pharmacology. Wide-ranging epidemiological surveys have demonstrated a surprisingly high lifetime prevalence amounting to 2–3% of the general population worldwide (Robins et al, 1984). Yet only a fraction of sufferers come forward for treatment and often the diagnosis is missed.

Information

Type
Research Article
Copyright
Copyright © The Royal College of Psychiatrists 1999 
Submit a response

eLetters

No eLetters have been published for this article.